$4.56B in CY2024 Part D spend1.1M claims · 203K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Dupilumab used for?
DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose diseas....
Is there a generic for Dupilumab?
No. Dupilumab is brand-only with no generic equivalents currently in market.
How much does my plan pay for Dupilumab?
Across 329 Part D plans, Dupilumab averages $1391.53/unit (NADAC). Lowest available: $1008.41/unit. Highest in distribution: $1774.75/unit.
Is Dupilumab on the FDA shortage list?
No. Dupilumab is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (4 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.